The original price of 19,000 fell to 648 such medical supplies began to purchase

1, a maximum drop of 95%, began to implementJanuary 10, according to Henan News Broadcasting, the results of the crown stent belt purchase has been officially landed in Henan Province, located in Zhengzhou City, Huazhong Outside Hospital intervention operating room, patients officially use the reduced price of the stent - from the original price of 19,000 yuan to 648 yuan.Gao Chuanyu, vice president of Hua zhongxuan Hospital, said that in 2020 there will be about 80,000 cardiac interventional operations in Henan Province, and that the new price list will be implemented from January 10, 2021, with most products being offered new medical prices and are in the reimbursement range.On November 5, 2020, the results of the purchase of crown bracket belt volume were announced, compared with 2019, the same enterprise's average price reduction of the same products 93%, the average price reduction of domestic products 92%, the average price reduction of imported products 95%, the price of armed enterprises less than 500 yuan, the top 10 quotations are below 800 yuan.It is understood that, in order to match the crown vein bracket, Henan Province and Guangdong and other seven provinces formed a coalition to carry out the crown pulse balloon centralized belt procurement, on December 22 last year produced the results of the election.The average price of expansion balloons decreased by 92.23 percent, the highest decline of 96.34 percent, and the average selling price of expansion balloon products in our province decreased from 3,166 yuan to 265 yuan.The average decrease of drug balloons applicable to small vascular diseases, fork diseases and in-scaffolding lesions was 44.45 percent, with a maximum decrease of 52.84 percent, and the average price of drug balloon products sold in Henan Province decreased from 24,200 yuan to 13,191 yuan.In addition, matching devices, patches, medical film for Henan and Chongqing, Yunnan, Guizhou Alliance procurement products. The average decline was 73.13 per cent, the highest decline was 97.76 per cent, the average drop was 79.64 per cent, the highest decline was 96.11 per cent, and the average decline for medical film was 48.97 per cent, or 61.48 per cent.2, sales enough, perhaps does not affect the development of enterprisesChina Medical Equipment Association Information Interaction and Integration Branch member, China Medical Materials Association Smart Medical Branch member Chen Song has published an article analysis in the "China Health" magazine, listed medical device enterprises generally show high gross margin, high cost of the basic financial outlook.High-value medical supplies raw material costs and production costs are not really high, but research and development investment is huge, sales costs are even higher.High-end medical device products generally adopt the "high pricing, high cost" marketing strategy, has its inevitable market logic. Take A, B, C three similar efficacy products as an example: A product pricing 10,000 yuan, 70% (i.e. 7000 yuan) for marketing, academic marketing, doctor education and rebates and other marketing activities;B product pricing 5000 yuan, of which40% (i.e. 2000 yuan) for the corresponding marketing activities;From the point of view of corporate profits, 3 kinds of product enterprises profit is 3000 yuan. But for doctors, almost the vast majority of knowledge, usage techniques and clinical experience with the product come from product A;Therefore, most enterprises that choose A product marketing strategy get high profits and can further invest in research and development, thus forming a new sustainable development path. And choose C product marketing strategy of the enterprise, will be quickly eliminated by the market.The fundamental principle of centralized procurement is "quantity-for-price". For production enterprises, "high pricing, high cost" marketing model can not bring more profits for enterprises, if you can get sufficient sales protection to eliminate high market costs, in fact, does not affect the normal development of production enterprises, but can be simplified marketing and get a better environment for survival and development. For doctors, centralized procurement results are the choice of varieties made on behalf of patients by health insurance payment agencies, and the quality of their products is additionally guaranteed, which in fact relieves the pressure on doctors to choose clinical varieties, allows doctors to obtain a more simple clinical environment, and avoids the patient challenges faced in product selection. (Cypress Blue Equipment)